David E. Gerber

DPP9-mediated inflammasome repression protects against checkpoint inhibitor lung toxicity

The paper identifies DPP9 as a genetic susceptibility gene for checkpoint inhibitor pneumonitis and shows IL-18 blockade could be a therapeutic strategy.

A novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models

This paper develops a novel MICA/B-targeting antibody that enhances NK cell activity and shows therapeutic efficacy in KRAS LKB1 mutant lung cancer models.

Differences in systemic immune parameters in individuals with lung cancer according to race

The paper compares systemic immune parameters between Black and White lung cancer patients, finding significant differences in cytokine levels and immune cell populations.

Cmai: Predicting Antigen-Antibody Interactions from Massive Sequencing Data

Cmai predicts antigen-antibody interactions from high-throughput BCR sequencing data, revealing immune responses to tumor antigens and ICI treatment outcomes.